Trial intelligence / Profile preview

Group vs. Individual MDMA-Assisted Therapy in PTSD Patients Diagnosed Following the Events of October 7, 2023

NCT07469098Phase 2Recruiting

Sponsor
Sheba Medical Center
Start
Dec 2025
Primary completion
Dec 2028
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Sheba Medical Center. Started Dec 2025; status: recruiting.

02

Drugs

midomafetamine
03

Conditions

post-traumatic stress disorder (PTSD)

Beyond the preview

Go deeper on NCT07469098.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07469098.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call